Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP

See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.

Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

Diabetes Canada Clinical Practice Guidelines

Type 2 Diabetes, FARXIGA® (dapagliflozin) 5 mg & 10 mg tablets

A1C and Weight Results RYBELSUS® (semaglutide) tablets 7 mg or 14 mg

Ozempic® vs. Trulicity®: SUSTAIN 7 Clinical Trial Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg

PDF) Shared decision making in type 2 diabetes with a support decision tool that takes into account clinical factors, the intensity of treatment and patient preferences: Design of a cluster randomised (OPTIMAL)

Perspectives of glycemic variability in diabetic neuropathy: a comprehensive review

A1C & Glycemic Control Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial, Cardiovascular Diabetology

Nutrients, Free Full-Text